The short version of cAMP signaling fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-08. Anything still debated is marked as such rather than presented as settled.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
| Property | Value | Notes |
|---|---|---|
| Primary marker | Insulin-like growth factor 1 | Slow-changing integrated indicator of axis activity |
| Secondary marker | Growth hormone | Pulsatile; requires repeated or timed sampling |
| Typical analytical method | Immunoassay | Antibody-based quantification in serum |
| Common sample matrix | Serum | Collected under standardized conditions |
| Key interpretation factor | Age-stratified reference ranges | Baseline marker concentrations shift with age |
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
=== Immobilized metal ion affinity chromatography === Immobilized metal ion affinity chromatography (IMAC) is based on the specific coordinate covalent bond of amino acids, particularly histidine, to metals. This technique works by allowing proteins with an affinity for metal ions to be retained in a column containing immobilized metal ions, such as cobalt, nickel, or copper for the purification of histidine-containing proteins or peptides, iron, zinc or gallium for the purification of phosphorylated proteins or peptides. Many naturally occurring proteins do not have an affinity for metal ions, therefore recombinant DNA technology can be used to introduce such a protein tag into the relevant gene. Methods used to elute the protein of interest include changing the pH, or adding a competitive molecule, such as imidazole.
RNA endonuclease nucleotidyl transferase phosphotransferase phosphatase ligase kinase glucano transferase RNA may catalyze folding of the pathological protein conformation of a prion in a manner similar to that of a chaperonin.
Georg, German-trained medicinal chemist, professor of medicinal chemistry in the US Ellen Gleditsch (1879–1968), Norwegian radiochemist Paula T. Hammond (1963-), American chemical engineer, MIT professor Anna J. Harrison (1912–1998), American organic chemist Remziye Hisar (1902–1992), Turkish chemist, first woman chemist of Turkey Darleane C. Hoffman (1926–2025), American Nuclear chemist Icie Hoobler (1892–1984), American biochemist Dorothy Crowfoot Hodgkin (1910–1994), British crystallographer, Nobel prize in chemistry 1964 Donna M. Huryn, American organic chemist Clara Immerwahr (1870–1915), German chemist Allene Rosalind Jeanes (1906–1995), American organic chemist Malika Jeffries-EL, American organic chemist Irène Joliot-Curie (1897–1956), French chemist and nuclear physicist, Nobel Prize in Chemistry 1935 Madeleine M.
== Release == Stargirl premiered on DC Universe on May 18, 2020, with the first season consisting of 13 episodes. The series was originally intended to premiere on May 11, seven days before its official release. The series was released in 4K Ultra HD on DC Universe. In November 2019, The CW announced to broadcast each episode the day after it premieres on the streaming service, with each episode available to stream on The CW's online platforms after its broadcast. Stargirl started airing on The CW on May 19, 2020, at 8 pm. Some episodes have content removed when they air on The CW to allow for the network's commercials, notably approximately eight minutes in each of the first two episodes. DC Universe streamed the full episodes, and Johns said starting with the third episode, both releases are "almost identical". The series release plans shifted and it stayed in post-production longer to accommodate the broadcast on The CW to accomplish the adjustments that had to be made. Scenes removed in the first episode from The CW broadcast included: establishing shots of Barbara Whitmore's new job, and Pat's auto shop; an interaction between Courtney and Cindy Burman in the halls of Blue Valley High School that Alex Zalben of Decider said was "clear set-up for later" but helped strengthen Courtney's emotional arc; and Mark Ashworth's scenes as "a mysterious, extremely creepy bearded janitor", which Zalben said was more of "a fun Easter egg that will pay dividends down the road"; and Courtney finding a newspaper article about Starman and Stripesy.
Sources: en.wikipedia.org
The first pass through the hepatic portal vein results in some of the drug being metabolized by O-demethylation into an active metabolite of dextromethorphan called dextrorphan, the 3-hydroxy derivative of dextromethorphan. The therapeutic activity of dextromethorphan is believed to be caused by both the drug and this metabolite. Dextromethorphan also undergoes N-demethylation (to 3-methoxymorphinan or MEM), and partial conjugation with glucuronic acid and sulfate ions. Hours after dextromethorphan therapy, (in humans) the metabolites (+)-3-hydroxy-N-methylmorphinan and (+)-3-morphinan and traces of the unchanged drug are detectable in the urine. A major metabolic catalyst involved is the cytochrome P450 enzyme known as 2D6, or CYP2D6. A significant portion of the population has a functional deficiency in this enzyme and are known as poor CYP2D6 metabolizers. O-demethylation of dextromethorphan to dextrorphan contributes to at least 80% of the dextrorphan formed during dextromethorphan metabolism. As CYP2D6 is a major metabolic pathway in the inactivation of dextromethorphan, the duration of action and effects of dextromethorphan can be increased by as much as three times in such poor metabolizers. In one study on 252 Americans, 84.3% were found to be "fast" (extensive) metabolizers, 6.8% to be "intermediate" metabolizers, and 8.8% were "slow" metabolizers of dextromethorphan. A number of alleles for CYP2D6 are known, including several completely inactive variants. The distribution of alleles is uneven amongst ethnic groups.
==== Follicular lumen ==== The follicular lumen is the fluid-filled space within a follicle of the thyroid gland. There are hundreds of follicles within the thyroid gland. A follicle is formed by a spherical arrangement of follicular cells. The follicular lumen is filled with colloid, a concentrated solution of thyroglobulin and is the site of synthesis of the thyroid hormones thyroxine (T4) and triiodothyronine (T3).
After the Habsburg hereditary lands had been divided by the 1379 Treaty of Neuberg, Tyrol was ruled by the descendants of Duke Leopold III of Austria. After a second division within the Leopoldinian line in 1406, Duke Frederick IV of the Empty Pockets ruled them. In 1420 he made Innsbruck the Tyrolean capital. In 1490 his son and heir Sigismund renounced Tyrol and Further Austria in favour of his cousin German King Maximilian I of Habsburg. By then Maximilian I had re-united all Habsburg lands under his rule. In 1500 he also acquired the remaining Gorizia (Görz) territories around Lienz and the Puster Valley. When Emperor Ferdinand I died in 1564, he bequeathed the rule over Tyrol and Further Austria to his second son Archduke Ferdinand II. Both territories thereafter fell to the younger sons of the Habsburg Emperors: Archduke Matthias in 1608 and Maximilian III in 1612. After the death of Archduke Sigismund Francis in 1665, all Habsburg lands were again under the united rule of the Emperor Leopold I.
Sources: en.wikipedia.org
For example, if it is predicted that the transition state structure has a build-up of negative charge relative to the ground state structure, then electron-donating groups would be expected to increase the rate of the reaction. Other LFER scales have been developed. Steric and polar effects are analyzed through Taft Parameters. Changing the solvent instead of the reactant can provide insight into changes in charge during the reaction. The Grunwald-Winstein Plot provides quantitative insight into these effects.
Before the formation of Alice in Chains, Layne Staley, a drummer at the time, landed his first gig as a vocalist when he auditioned to sing for a local glam metal band known as Sleze after receiving some encouragement from his stepbrother Ken Elmer. Other members of this group at that time were guitarists Johnny Bacolas and Zoli Semanate, drummer James Bergstrom, and bassist Byron Hansen. This band went through several lineup changes culminating with Nick Pollock as their sole guitarist and Bacolas switching to bass before discussions arose about changing their name to Alice in Chains. This was prompted by a conversation that Bacolas had with Russ Klatt, the lead singer of Slaughter Haus 5, about backstage passes. One of the passes said "Welcome to Wonderland", and they started talking about that being a reference to Alice in Wonderland, until Klatt said, "What about Alice in Chains? Put her in bondage and stuff like that." Bacolas liked the name "Alice in Chains" and brought it up to his bandmates; they agreed and decided to change the band's name. Due to concerns over the reference to female bondage, the group ultimately chose to spell it differently as Alice N' Chains to allay any parental concerns, though Staley's mother Nancy McCallum has said she was still not happy with this name at first. According to Bacolas, the decision to use the apostrophe-N combination in their name had nothing to do with the band Guns N' Roses. The name change happened a year before Guns N' Roses became a household name with their first album, Appetite for Destruction, released in July 1987.
On January 4, 2008, the results of a mitochondrial DNA test, comparing the child's DNA with that of his potential grandmother, Clara de Rojas, were revealed by the Colombian government. It was reported that there was a very high probability that the boy was indeed part of the Rojas family. The same day, FARC released a communique in which they admitted that Emmanuel had been taken to Bogotá and "left in the care of honest persons" for safety reasons until a humanitarian exchange took place. The group accused President Uribe of "kidnapping" the child to sabotage his liberation. However, on January 10, 2008, FARC released Rojas and Gonzalez through a humanitarian commission headed by the International Committee of the Red Cross. On January 13, 2008, Venezuelan President Hugo Chávez stated his disapproval with the FARC strategy of armed struggle and kidnapping saying, "I don't agree with kidnapping and I don't agree with armed struggle". He repeated his call for a political solution and an end to the war in March and June 2008: "The guerrilla war is history...At this moment in Latin America, an armed guerrilla movement is out of place". In February 2008, FARC released four other political hostages "as a gesture of goodwill" toward Chávez, who had brokered the deal and sent Venezuelan helicopters with Red Cross logos into the Colombian jungle to pick up the freed hostages. On March 1, 2008, the Colombian armed forces launched a military operation 1.8 kilometres into Ecuador on a FARC position, killing 24, including Raúl Reyes, member of the FARC Central High Command.
Sources: en.wikipedia.org
It varies slowly and reflects cumulative axis activity rather than momentary secretion. Growth hormone is released in pulses affected by sleep, stress, and meals, making single readings hard to interpret. The slower marker gives a more stable picture across a study period.
Assay calibration and antibody specificity differ between platforms, so identical samples can yield different numbers. A method change within one laboratory can shift results without any biological change. Cross-validation is often needed for multi-site work.
They capture only one moment in a pulsatile pattern and are strongly influenced by recent activity and meals. Repeated sampling or overnight profiles provide a more representative view. Provocative testing is an alternative when a dynamic response is of interest.
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.